These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9649162)

  • 1. A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).
    Warner E; Goel R; Chang J; Chow W; Verma S; Dancey J; Franssen E; Dulude H; Girouard M; Correia J; Gallant G
    Br J Cancer; 1998 Jun; 77(12):2376-80. PubMed ID: 9649162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
    Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
    J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
    Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
    Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
    Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
    Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
    Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
    Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carcinoma of unknown primary site.
    Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
    Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.
    Mikhail S; Lustberg MB; Ruppert AS; Mortazavi A; Monk P; Kleiber B; Villalona-Calero M; Bekaii-Saab T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1005-12. PubMed ID: 26416564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
    Rigg A; Cunningham D; Gore M; Hill M; O'Brien M; Nicolson M; Chang J; Watson M; Norman A; Hill A; Oates J; Moore H; Ross P
    Br J Cancer; 1997; 75(1):101-5. PubMed ID: 9000605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC; Ettinger DS; Neuberg D; Comis RL; Ruckdeschel JC; Bonomi PD; Johnson DH
    J Clin Oncol; 1995 Jul; 13(7):1615-22. PubMed ID: 7602350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
    J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.
    Thiery-Vuillemin A; Dobi E; Nguyen T; Royer B; Montange D; Maurina T; Kalbacher E; Bazan F; Villanueva C; Demarchi M; Chaigneau L; Ivanaj A; Pivot X
    Anticancer Drugs; 2010 Nov; 21(10):958-62. PubMed ID: 20856105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site.
    Piga A; Nortilli R; Cetto GL; Cardarelli N; Fedeli SL; Fiorentini G; D'Aprile M; Giorgi F; Parziale AP; Contu A; Montironi R; Gesuita R; Carle F; Cellerino R
    Br J Cancer; 2004 May; 90(10):1898-904. PubMed ID: 15138469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma: association with severe myelotoxicity.
    Bar-Sela G; Tsalic M; Gaitini D; Steiner M; Haim N
    Med Oncol; 2003; 20(3):291-4. PubMed ID: 14514979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Rose PG; Rodriguez M; Waggoner S; Greer BE; Horowitz IR; Fowler JM; McGuire WP
    J Clin Oncol; 2000 Aug; 18(16):2957-62. PubMed ID: 10944128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study.
    Briasoulis E; Tsavaris N; Fountzilas G; Athanasiadis A; Kosmidis P; Bafaloukos D; Skarlos D; Samantas E; Pavlidis N
    Oncology; 1998; 55(5):426-30. PubMed ID: 9732220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.